Accordingly, the use of a PI3K inhibitor (wortmannin) in combination with anti-estrogens, the selective estrogen receptor modulator tamoxifen, or the selective estrogen receptor down-regulator fulvestrant, resulted in increased tumor suppression to a greater extent than either inhibitor alone [87]. The gene discussed is PIK3CD; the disease is neoplasm.